Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Efficient Optimization and Synthesis of Diverse Azaarenes via Nitrogen Atom Insertion under Continuous Flow Conditions

10 June 2025, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

We report the development of a continuous flow approach to nitrogen atom insertion. The setup is modular, enabling the rapid optimization of reaction conditions for a wide range of substrates. The milder reaction conditions led to an improved substrate scope and functional group tolerance compared to batch conditions. The reactions can also be safely scaled up to preparative scale.

Keywords

continuous flow
nitrogen insertion
indole
quinazoline

Supplementary materials

Title
Description
Actions
Title
SI
Description
SI
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Jun 10, 2025 Version 1

Metrics

214
209
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv-2025-04rxt
D O I: 10.26434/chemrxiv-2025-04rxt [opens in a new tab]

Funding

Innosuisse - Schweizerische Agentur für Innovationsförderung
Innosuisse (48934.1 IP-LS - Fast-track optimization platform to accelerate drug discovery).
Fonds der Chemischen Industrie
ASKP scholarship

Author’s competing interest statement

The authors declare the following competing financial interest(s): Q.L. is an employee, and T.C.F. is CEO of SpiroChem AG, a Innovative Contract Research Organization (iCRO) commercializing products and services.

Ethics

The author(s) have declared ethics committee/IRB approval is not relevant to this content

Share